{"id":"W3135213711","doi":"10.1016/j.ccell.2021.02.013","title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","year":2021,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":517,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Human Genome Research Institute; Genentech; EMD Serono; Fondation de France; Eisai; Parker Institute for Cancer Immunotherapy; Danmarks Frie Forskningsfond; Kay Kendall Leukaemia Fund; Celldex Therapeutics; National Institutes of Health; BioMarin Pharmaceutical; Harvard Medical School; National Cancer Institute; Chinook Therapeutics; Gilead Sciences; G. Harold and Leila Y. Mathers Foundation; Dermatology Foundation; Leukemia and Lymphoma Society; Novartis; Bristol-Myers Squibb; Dana-Farber/Harvard Cancer Center; Merck; GlaxoSmithKline; Dana-Farber Cancer Institute; Roche; Astellas Pharma US; Pfizer; U.S. Department of Defense; Eli Lilly and Company; AstraZeneca; American Association for Cancer Research; Conquer Cancer Foundation; Exelixis","keywords":"Immune system; Immunotherapy; Cancer research; Tumor microenvironment; Clear cell renal cell carcinoma; CD8; Renal cell carcinoma; Biology; T cell; Myeloid; Cytotoxic T cell; Cell; Immunology; Cancer; Medicine; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000547025,0.0002025637,0.000356192,0.0008893394,0.0003581489,0.0006863013,0.0002761192,0.0004013529,0.001522258],"category_scores_gemma":[0.001297906,0.0001303685,0.0002027535,0.0009805593,0.0003228413,0.0005239809,0.0003715715,0.0006022812,0.000280051],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003060849,"about_ca_system_score_gemma":0.0003832323,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001285346,"about_ca_topic_score_gemma":0.001311339,"domain_scores_codex":[0.9998368,0.00004299169,0.00001435527,0.00002978004,0.00003681657,0.00003930389],"domain_scores_gemma":[0.9992162,0.000154005,0.0003130271,0.00004749565,0.0001087228,0.0001604488],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002205226,0.0001494607,0.9530886,0.00008990333,0.00006264316,0.0012489,0.0002886327,0.000301689,0.01445997,0.0003032475,0.000439358,0.02736231],"study_design_scores_gemma":[0.0000184347,0.0004402369,0.9923059,0.00001989592,0.00004801398,0.002364624,0.0002566095,0.0006804643,0.002274177,0.0003185609,0.00126526,0.000007799754],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953608,0.002244488,0.0003713782,0.0001263651,0.00001553154,0.00001405539,0.0001823319,0.00002031543,0.001664672],"genre_scores_gemma":[0.9983412,0.0006434602,0.0002835275,0.00004599239,0.00003279385,0.000007111775,0.0001379345,0.000002898871,0.0005051379],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001522258,"threshold_uncertainty_score":0.005092382,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008063668867447894,"score_gpt":0.245670689036705,"score_spread":0.2376070201692571,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}